GlassScriptPhysician profile
Paras Patel
NPI 1225492895
$10,429.36
in general payments reported to CMS, 2019-2025
24 companies · $2,389 in 2025
The $2,389 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $830 · 2023: $3,037 · 2024: $4,174 · 2025: $2,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,058 · Travel and Lodging: $3,382 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,057.97 |
| Travel and Lodging | $3,382.36 |
| Education | $158.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,447.05 | 2022-2025 | Micra, Azure Xt Dr Mri Surescan, Linq II |
| Boston Scientific Corporation | $2,788.75 | 2022-2025 | Farapulse, Watchman Flx, Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $1,861.30 | 2024-2025 | Aveir, Ensite, Gallant |
| Biosense Webster, INC. | $481.67 | 2024-2025 | Carto 3, Qdot Micro Catheter |
| Philips North America LLC | $377.91 | 2024-2025 | (9520) Igt Devices Undivided, Event, (Ck4) Mcot |
| Amgen INC. | $188.40 | 2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $177.51 | 2024-2025 | Camzyos, Eliquis |
| Atricure, INC. | $142.81 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Novo Nordisk INC | $126.55 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $116.15 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $113.07 | 2024-2025 | Farxiga |
| Esperion Therapeutics, INC. | $96.96 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $92.89 | 2024-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $74.06 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $61.49 | 2025 | Onpattro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $52.14 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.75 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $37.96 | 2024 | Arcalyst |
| Pfizer INC. | $30.94 | 2025 | |
| Edwards Lifesciences Corporation | $27.47 | 2025 | Sapien 3 Ultra Resilia |
| Cardiva Medical, INC. | $26.45 | 2024 | Optowire |
| Actelion Pharmaceuticals US, INC. | $22.89 | 2024 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $21.82 | 2025 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.37 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paras Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.